Literature DB >> 9355739

Expression, purification and characterization of recombinant caprine N-acetylglucosamine-6-sulphatase.

T Litjens1, J Bielicki, D S Anson, K Friderici, M Z Jones, J J Hopwood.   

Abstract

Mucopolysaccharidosis type IIID or Sanfilippo D syndrome is a lysosomal storage disorder caused by the deficiency of N-acetylglucosamine-6-sulphatase (Glc6S). In addition to human patients, a Nubian goat with this disorder has been described and the caprine Glc6S (cGlc6S) cDNA cloned. In this study, the full-length cGlc6S cDNA was inserted into the expression vector, pEFNeo, which placed the cGlc6S cDNA under the transcriptional control of the human polypeptide chain elongation factor promoter. The pEFNeo expression vector also contains the human growth hormone polyadenylation signal and the genes encoding resistance to ampicillin and G418. The cGlc6S expression construct was electroporated into Chinese hamster ovary (CHO-K1) cells, and stably transfected clones were isolated. One clone, CHOrcGlc6S.17, which secreted the highest Glc6S activity into the culture medium, was selected and cultured in cell factories. The secreted recombinant cGlc6S (rcGlc6S) precursor was purified to homogeneity from conditioned medium by a two-column procedure which consisted of a Cu2+-chelating Sepharose column followed by TSK G3000SW gel filtration. The native molecular mass of rcFlc6S was estimated to be 102 kDa and the subunit size was 94 kDa. The kinetic properties of cGlc6S were similar to those of human Glc6S isolated from liver. rcGlc6S was endocytosed by fibroblasts from patients with mucopolysaccharidosis type IIID via the mannose 6-phosphate receptor-mediated pathway resulting in correction of the storage phenotype of these cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355739      PMCID: PMC1218767          DOI: 10.1042/bj3270089

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Studies on glucosaminidase. 4. The fluorimetric assay of N-acetyl-beta-glucosaminidase.

Authors:  D H LEABACK; P G WALKER
Journal:  Biochem J       Date:  1961-01       Impact factor: 3.857

2.  Correction of Sanfilippo A skin fibroblasts by retroviral vector-mediated gene transfer.

Authors:  J Bielicki; J J Hopwood; D S Anson
Journal:  Hum Gene Ther       Date:  1996-10-20       Impact factor: 5.695

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.

Authors:  A C Crawley; D A Brooks; V J Muller; B A Petersen; E L Isaac; J Bielicki; B M King; C D Boulter; A J Moore; N L Fazzalari; D S Anson; S Byers; J J Hopwood
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

6.  Expression, purification and characterization of recombinant human N-acetylgalactosamine-6-sulphatase.

Authors:  J Bielicki; M Fuller; X H Guo; C P Morris; J J Hopewood; D S Anson
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

7.  Cloning and sequence analysis of caprine N-acetylglucosamine 6-sulfatase cDNA.

Authors:  K Friderici; K T Cavanagh; J R Leipprandt; C E Traviss; D S Anson; J J Hopwood; M Z Jones
Journal:  Biochim Biophys Acta       Date:  1995-06-09

8.  Insulin fragments as a carrier for peptide delivery across the blood-brain barrier.

Authors:  M Fukuta; H Okada; S Iinuma; S Yanai; H Toguchi
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

9.  N-Acetylglucosamine-6-sulfate sulfatase from human urine.

Authors:  R Basner; H Kresse; K von Figura
Journal:  J Biol Chem       Date:  1979-02-25       Impact factor: 5.157

10.  Sanfilippo disease type D: deficiency of N-acetylglucosamine-6-sulfate sulfatase required for heparan sulfate degradation.

Authors:  H Kresse; E Paschke; K von Figura; W Gilberg; W Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

View more
  12 in total

1.  Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.

Authors:  E Downs-Kelly; M Z Jones; J Alroy; K T Cavanagh; B King; R E Lucas; J C Baker; S A Kraemer; J J Hopwood
Journal:  J Mol Neurosci       Date:  2000-12       Impact factor: 3.444

2.  Sequence analysis of heparan sulphate and heparin oligosaccharides.

Authors:  R R Vivès; D A Pye; M Salmivirta; J J Hopwood; U Lindahl; J T Gallagher
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

3.  Recombinant human sulphamidase: expression, amplification, purification and characterization.

Authors:  J Bielicki; J J Hopwood; E L Melville; D S Anson
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

4.  Recombinant caprine 3H-[N-acetylglucosamine-6-sulfatase] and human 3H-[N-acetylgalactosamine-4-sulfatase]: plasma clearance, tissue distribution, and cellular uptake in the rat.

Authors:  M Z Jones; L K Brumfield; B M King; J J Hopwood; S Byers
Journal:  J Mol Neurosci       Date:  1998-12       Impact factor: 3.444

5.  A strategy for rapid sequencing of heparan sulfate and heparin saccharides.

Authors:  J E Turnbull; J J Hopwood; J T Gallagher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 6.  Sulfatase activities towards the regulation of cell metabolism and signaling in mammals.

Authors:  M Buono; Maria Pia Cosma
Journal:  Cell Mol Life Sci       Date:  2009-11-22       Impact factor: 9.261

7.  Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase.

Authors:  Xianxuan Zhou; Lingyun Li; Robert J Linhardt; Jian Liu
Journal:  FEBS J       Date:  2013-03-06       Impact factor: 5.542

8.  Overexpression of inactive arylsulphatase mutants and in vitro activation by light-dependent oxidation with vanadate.

Authors:  Terri M Christianson; Chris M Starr; Todd C Zankel
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

9.  Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans.

Authors:  Megumi Morimoto-Tomita; Kenji Uchimura; Zena Werb; Stefan Hemmerich; Steven D Rosen
Journal:  J Biol Chem       Date:  2002-10-03       Impact factor: 5.157

10.  Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-N-Acetylglucosamine-6-Sulfatase in Neonatal Mice.

Authors:  Feng Wang; Derek R Moen; Chelsee Sauni; Shih-Hsin Kan; Shan Li; Steven Q Le; Brett Lomenick; Xiaoyi Zhang; Sean Ekins; Srikanth Singamsetty; Jill Wood; Patricia I Dickson; Tsui-Fen Chou
Journal:  Mol Pharm       Date:  2020-12-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.